This principle is likely to guide future medication development as researchers explore triple agonists and other multi-targeted approaches
Stimulates insulin release and reduces liver glucose production for better glycemic control while curbing appetite and supporting your body's use of stored fat for energy
These data come from Cosmos, a HIPAA-defined Limited Data Set of more than 214 million patients from 218 Epic organizations including 1,235 hospitals and more than 26,800 clinics, serving patients in all 50 states and Lebanon
We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development
GLP-1 receptor agonists stimulate glucose-dependent insulin secretion, meaning they prompt the pancreas to release insulin when blood sugar rises after eating
Avoid Saxenda in patients with a history of suicidal attempts or active suicidal ideation
